Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
GAIN-BCG trial: what clinicians have said so far
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- NCT07000084 ↗
- Recruiting
- Alliance for Clinical Trials in Oncology
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on GAIN-BCG (recurrent BCG-exposed high-grade non-muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GAIN-BCG so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8
- Interventions
- BCG Solution; Biopsy of Bladder; Cystoscopy; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Transurethral Resection of Bladder Tumor; Gemcitabine
- Arms
- Arm A (BCG) · Active comparator
- Arm B (BCG and gemcitabine) · Experimental
- Enrollment
- 330 (estimated)
- Primary outcomes
- High Grade Recurrence-free survival (HG-RFS)
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Jul 17, 2025
- Primary completion
- Jun 5, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07000084 · updated Oct 2, 2026
Publications
linked from the registry- Gaffney CD, Alam SM, Wald G, Sjoberg D, Eichholz J, Sarungbam J, D'Souza N, Lavery J, Hernandez C, Tomerlein M, Zagajeski P, Hildreth KW, Donat S, Smith R, Donahue T, Goh A, Bochner B, Al-Ahmadie H, Pietzak E. A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guerin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer. J Urol. 2026 Oct 1:101097JU0000000000005324. doi: 10.1097/JU.0000000000005324. Online ahead of print. PubMed 42821609